GlaxoSmithKline (GSK) receives FDA approval in May 2013, for two orphan drugs for the treatment of patients with advanced or unresectable melanoma :
Both drugs are approved as single agents, not as a combination treatment. Tafinlar, a BRAF inhibitor, is approved for melanoma whose tumors express the BRAF V600E gene mutation. Mekinist, a MEK inhibitor, is approved for melanoma whose tumors express the BRAF V600E or V600K gene mutations.